Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC trimmed its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 4.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 104,483 shares of the company's stock after selling 5,314 shares during the quarter. Medpace accounts for approximately 1.9% of Rice Hall James & Associates LLC's portfolio, making the stock its 10th biggest position. Rice Hall James & Associates LLC owned about 0.34% of Medpace worth $34,712,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of MEDP. Iron Triangle Partners LP purchased a new stake in shares of Medpace in the 3rd quarter valued at approximately $64,371,000. Wellington Management Group LLP increased its holdings in Medpace by 36.0% in the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock valued at $138,612,000 after purchasing an additional 109,886 shares during the last quarter. DF Dent & Co. Inc. raised its position in Medpace by 189.9% in the third quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company's stock valued at $53,841,000 after purchasing an additional 105,659 shares during the period. Argent Capital Management LLC lifted its stake in Medpace by 431.5% during the third quarter. Argent Capital Management LLC now owns 91,732 shares of the company's stock worth $30,620,000 after purchasing an additional 74,473 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec acquired a new position in Medpace during the third quarter worth $23,321,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. TD Cowen cut their price objective on Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a report on Wednesday, October 23rd. Robert W. Baird increased their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. Finally, Baird R W cut shares of Medpace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $381.44.

Medpace Stock Up 0.3 %

MEDP traded up $1.19 on Thursday, reaching $345.15. The company's stock had a trading volume of 230,786 shares, compared to its average volume of 274,758. The company has a market capitalization of $10.52 billion, a price-to-earnings ratio of 27.33, a P/E/G ratio of 3.77 and a beta of 1.36. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77. The stock has a 50 day moving average of $343.28 and a two-hundred day moving average of $347.47.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.